rituximab,ibrutinib,Bendamustine
biogen,roche,novartis,janssen,abbvie
['lymsm', 'improve']
phase iii rct of br +/- ibrutinib followed by r maint in elderly mcl. median pfs improvement of 2.3 years, but no os difference. ~4% grade &gt;3 afib with ibrutinib. #lymsm #asco22 
Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. ??????